Our Pricing

The Science Behind Mounjaro Jab

Published on: June 03, 2026

Understanding how does Mounjaro work UK helps patients make informed treatment decisions. Mounjaro (tirzepatide) is the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management, working through two complementary hormone pathways rather than one. This innovative mechanism has produced weight loss results exceeding previous single-pathway treatments in head-to-head clinical trials.

How Does Mounjaro Work: The Dual-Agonist Mechanism

Mounjaro contains tirzepatide, which activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors simultaneously [1]. This dual action represents a fundamental departure from earlier weight loss injections that target only GLP-1 pathways. By engaging both receptor systems, tirzepatide enhances insulin secretion when blood glucose rises, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways.

The GIP component—absent in semaglutide-based treatments—appears to amplify metabolic benefits beyond appetite suppression alone. In the SURPASS-2 trial comparing tirzepatide directly to semaglutide 1mg, patients on the highest tirzepatide dose (15mg) achieved 12.4kg average weight loss versus 6.2kg with semaglutide over 40 weeks [1]. This dual mechanism explains why Mounjaro frequently produces greater weight reduction than single-agonist alternatives.

Once injected subcutaneously, tirzepatide reaches peak plasma concentration within 8-72 hours and maintains therapeutic levels for approximately one week, enabling once-weekly dosing [2]. The medication's half-life of around 5 days ensures stable hormone receptor activation between doses, which helps maintain consistent appetite control throughout the week.

Clinical Trial Evidence: SURPASS Programme Results

Weight Loss Outcomes in Real Patients

The SURPASS-3 trial demonstrated that adults with obesity achieved average weight reductions of 15.0%, 19.5%, and 22.5% with tirzepatide 5mg, 10mg, and 15mg doses respectively over 72 weeks [3]. These results exceeded the 5-10% weight loss typically seen with lifestyle interventions alone and surpassed outcomes from earlier pharmacological treatments.

Importantly, over half of participants on the highest Mounjaro dose achieved at least 20% body weight reduction—a threshold associated with significant improvements in obesity-related conditions including type 2 diabetes, hypertension, and sleep apnoea [3]. Clinical benefits extended beyond the number on the scale, with participants experiencing improvements in glycaemic control, blood pressure, and lipid profiles.

How Mounjaro Affects Appetite and Satiety

Tirzepatide's appetite-suppressing effects occur through multiple pathways. GLP-1 receptor activation in the hypothalamus and brainstem reduces hunger signals and increases feelings of fullness after meals [2]. Simultaneously, delayed gastric emptying means food remains in the stomach longer, prolonging satiety between meals and reducing the frequency of hunger episodes.

Patients typically report diminished food cravings, smaller portion sizes at meals, and reduced interest in high-calorie foods within the first few weeks of treatment. These subjective experiences align with objective measurements showing reduced caloric intake in clinical trials. Unlike stimulant-based appetite suppressants, tirzepatide works through natural incretin hormone pathways without causing jitteriness or sleep disturbance.

The dual GIP/GLP-1 action may also influence food reward pathways in the brain, potentially reducing hedonic eating behaviours—consumption driven by pleasure rather than physiological hunger [1]. This neurological component helps explain why patients often find it easier to adhere to reduced-calorie eating patterns whilst on Mounjaro compared to diet-only approaches.

Mounjaro vs Wegovy: Comparing the Science

Mechanism Differences That Matter

Wegovy contains semaglutide, a selective GLP-1 receptor agonist that activates only one incretin pathway. Mounjaro's additional GIP receptor activation appears to enhance weight loss beyond what GLP-1 stimulation achieves alone. Direct comparison trials show tirzepatide producing 2-5kg greater average weight reduction than semaglutide at equivalent treatment durations [1][3].

Both medications slow gastric emptying and reduce appetite, but tirzepatide's dual mechanism may offer advantages for patients who achieve suboptimal results with GLP-1-only treatments. The GIP component also influences fat metabolism and insulin sensitivity through pathways independent of appetite suppression, potentially benefiting metabolic health markers beyond weight reduction alone.

Dosing Schedule and How Treatment Progresses

Mounjaro treatment begins with a 2.5mg once-weekly dose for the first four weeks, allowing your body to adapt to the medication's effects whilst minimising gastrointestinal side effects. Your prescriber then increases the dose to 5mg weekly, with further escalations to 7.5mg, 10mg, 12.5mg, or 15mg at four-week intervals based on your weight loss response and tolerability [2].

This gradual dose escalation—built into the treatment protocol—helps optimise efficacy whilst reducing the likelihood of nausea, vomiting, or diarrhoea that can occur when starting incretin-based therapies. Most patients reach their maintenance dose within 16-20 weeks of starting treatment. Clinical trials demonstrate that higher doses produce greater weight loss, though individual response varies.

Each Mounjaro KwikPen contains four pre-filled doses at a single strength, administered via subcutaneous injection into the abdomen, thigh, or upper arm. The injection takes seconds to complete, and most patients find the process straightforward after their first dose. Rotating injection sites helps prevent lipodystrophy and ensures consistent medication absorption.

Who Can Benefit from Mounjaro Treatment

Clinical Criteria and Prescriber Assessment

Mounjaro is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidaemia [2]. Your UK prescriber will assess your medical history, current medications, and weight loss goals during your online consultation to determine whether tirzepatide represents an appropriate treatment option.

Certain medical conditions preclude Mounjaro use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy. Pregnancy and breastfeeding are also contraindications. Your prescriber will review these factors before issuing a prescription, ensuring treatment safety and suitability for your individual circumstances.

Scientific References

1. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/14881 [accessed 13 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modifications, and physical activity levels. Clinical trial data represents average outcomes and does not guarantee individual results.